


Learnings from the LOCOMOTIVE study:


Subgroup analyses: Spot stenting with DCB in high risk patients.

(Gunnar Tepe, MD, LINC 2020, oral presentation)


LOCOMOTIVE subgroup analysis:
Spot Stenting in long vs. short lesions



SFA Stent performance related to lesion length¹



LOCOMOTIVE subgroup analysis: Lesion location



* fTLR = Freedom from target lesion revascularization


¹ Weinstock B et al. Vascular Disease Management 2014;11(4):E76-E86

² Liistro et al. JACC 2013;6(12):1295-1302


Learnings from the LOCOMOTIVE study:

Subgroup analyses: Spot stenting with DCB in high risk patients.
(Gunnar Tepe, MD, LINC 2020, oral presentation)


Drug effect on patency: DCB needed to optimize the stent result in standard therapy?



LOCOMOTIVE subgroup analysis: POBA vs. DCB with Spot Stenting



LOCOMOTIVE subgroup analysis: Spot Stenting in long lesions with DCB



* fTLR = Freedom from target lesion revascularization